The challenge of managing and mitigating impurities in drug products remains a critical focus with recent advancements in pharma. Impurities can pose serious health risks to patients and the presence of impurities can affect the safety.
For pharma, maintaining stringent cleaning standards is non-negotiable. The stakes are high, and the margin for error is slim. Cross-contamination can compromise product quality, endanger patient safety, and lead to costly regulatory penalties.
Illumina, a US based biotechnology firm, declared that it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. Fluent's single-cell examination innovation takes out the requirement for...
Alembic Pharmaceuticals Ltd said that the US Food and Drug Administration has granted final approval for its generic Bromfenac ophthalmic solution, which is recommended for the treatment of postoperative inflammation and pain in patients who have...
60 Degrees Pharmaceuticals, Inc, a leading firm focused on growing new medicines for infectious ailments, reported morals endorsement of an open label, extended access study of the ARAKODA® routine of tafenoquine in blend with standard of care...
Amarin Corporation plc, an innovative pharmaceutical firm, stated that its commercial partner in Mainland China (China), EddingPharm (Edding), has gained regulatory approval for Vascepa (icosapent ethyl) from the National Medical Products...
Abbott, the global healthcare leader, launched its ‘Chakkar Ko Check Kar’ campaign in India to highlightanoften-overlooked balance disorder,vertigo, which affects close to 70 million people in India.Vertigo is a condition that can make people feel...
Antidote Technologies, a digital health firm that focuses on patient engagement to advance recruitment for clinical trials, and SEQSTER PDM Inc., the leading patient-centric healthcare technology company, declared an agreement to improve patient...
Get ready for the highly anticipated Cosmetics Ingredients Expo 2024, a premier event that will bring together the best minds and leading innovators in the cosmetics industry.
Ligand Pharmaceuticals, a biopharmaceutical company, delcared that it has forayed into a definitive contract to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma...